UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Zum gesellschaftlichen Nutzen pharmazeutischer Innovationen (Volume 35.0)

2018

Volltextzugriff (PDF)

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

British journal of psychiatry, 2005-08, Vol.187 (2), p.131-136

2005

Volltextzugriff (PDF)

Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext

PharmacoEconomics German Research Articles, 2013-04, Vol.11 (1), p.25-32

2013

Volltextzugriff (PDF)

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

Journal of medical economics, 2012-10, Vol.15 (5), p.844-861

2012

Volltextzugriff (PDF)

To what extent do the PANSS and CGI-S overlap?

Journal of clinical psychopharmacology, 2006-06, Vol.26 (3), p.303-307

2006

Volltextzugriff (PDF)

Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology

Current medical research and opinion, 2016-01, Vol.32 (1), p.147-154

2016

Volltextzugriff (PDF)

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

Journal of medical economics, 2015-10, Vol.18 (10), p.838-849

2015

Volltextzugriff (PDF)

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone

The journal of clinical psychiatry, 2004-04, Vol.65 (4), p.531-536

2004

Volltextzugriff (PDF)

Objektive Forschung der Pharmaindustrie ist möglich

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010-01, Vol.104 (3), p.177-183

2010

Volltextzugriff (PDF)

Objectivity in research in the pharmaceutical industry is possible

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010-01, Vol.104 (3), p.177-183

2010

Volltextzugriff (PDF)

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

Journal of medical economics, 2015-10, Vol.18 (10), p.787-796

2015

Volltextzugriff (PDF)

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

International clinical psychopharmacology, 2005-07, Vol.20 (4), p.213-221

2005

Volltextzugriff (PDF)

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

PharmacoEconomics, 2005-01, Vol.23 Suppl 1 (S1), p.49-61

2005

Volltextzugriff (PDF)

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

PharmacoEconomics, 2005-01, Vol.23 Suppl 1 (S1), p.35-47

2005

Volltextzugriff (PDF)

Objectivity in research in the pharmaceutical industry is possible

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010, Vol.104 (3), p.177

2010

Volltextzugriff (PDF)

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

Dementia and geriatric cognitive disorders, 2002-01, Vol.14 (2), p.84-89

2002

Volltextzugriff (PDF)

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for I year

British journal of psychiatry, 2005, Vol.187 (AOU), p.131-136

2005

Volltextzugriff (PDF)

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany: Costs and effects of the use of long-acting risperidone in the treatment of schizophrenia

PharmacoEconomics, 2005, Vol.23, p.49-61

2005

Volltextzugriff (PDF)

Long-Acting, Injectable Risperidone: The First Long-Acting, Atypical Antipsychotic: Improves Quality of Life

Quality of life research, 2002-11, Vol.11 (7), p.653-653

2002

Volltextzugriff (PDF)

Patient Satisfaction with Their Medication Increases during 1 Year of Treatment with Long-Acting Risperidone Injection

Quality of life research, 2002-11, Vol.11 (7), p.657-657

2002

Volltextzugriff (PDF)

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia : a Belgian cost-effectiveness analysis: Costs and effects of the use of long-acting risperidone in the treatment of schizophrenia

PharmacoEconomics, 2005, Vol.23, p.35-47

2005

Volltextzugriff (PDF)

Beurteilungskriterien für den Nutzen von Arzneimitteln

Zum Gesellschaftlichen Nutzen Pharmazeutischer Innovationen, 1994, Vol.35

1994

Volltextzugriff (PDF)

Tabellen- und Abbildungsverzeichnis

Zum Gesellschaftlichen Nutzen Pharmazeutischer Innovationen, 1994, Vol.35

1994

Volltextzugriff (PDF)

Das Arzneimittel im System gesundheitlicher Leistungserstellung

Zum Gesellschaftlichen Nutzen Pharmazeutischer Innovationen, 1994, Vol.35

1994

Volltextzugriff (PDF)

Literaturverzeichnis

Zum Gesellschaftlichen Nutzen Pharmazeutischer Innovationen, 1994, Vol.35

1994

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(24)

Publikationsform

Sprache

Englisch
(16)
Deutsch
(14)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Zum gesellschaftlichen Nutzen pharmazeutischer Innovationen (Volume 35.0)

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

To what extent do the PANSS and CGI-S overlap?

Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone

Objektive Forschung der Pharmaindustrie ist möglich

Objectivity in research in the pharmaceutical industry is possible

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Objectivity in research in the pharmaceutical industry is possible

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for I year

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany: Costs and effects of the use of long-acting risperidone in the treatment of schizophrenia

Long-Acting, Injectable Risperidone: The First Long-Acting, Atypical Antipsychotic: Improves Quality of Life

Patient Satisfaction with Their Medication Increases during 1 Year of Treatment with Long-Acting Risperidone Injection

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia : a Belgian cost-effectiveness analysis: Costs and effects of the use of long-acting risperidone in the treatment of schizophrenia

Beurteilungskriterien für den Nutzen von Arzneimitteln

Tabellen- und Abbildungsverzeichnis

Das Arzneimittel im System gesundheitlicher Leistungserstellung

Literaturverzeichnis

Suchergebnisse filtern